Skip to content
Screener

Arbutus Biopharma Corporation ABUS Q2 2026 earnings

Reported August 12, 2026 · Before market open

Revenue$1.0MBeat by $314.0K
EPS-$0.03Miss by $0.01
Revenue estimate$700.0K
EPS estimate-$0.02
“This has been an exciting quarter for our imdusiran development program. In addition to obtaining Fast Track designation from the FDA on this promising drug candidate, which has achieved functional cure in 10 chronic hepatitis B patients to date, we reached alignment with the FDA on the design of our Phase 2b clinical trial. I would like to publicly congratulate our research and development team for their hard work and dedication in achieving these important milestones.”
Lindsay Androski

Next report

Nov 16, 2026 (in a month)
Revenue estimate$1.0M
EPS estimate-$0.02

Financials

Q2 2026

Income statement

See full
Revenue$1.0M-90.6%
Operating income-$6.0M-501%
Net income-$5.1M-304%
EPS (diluted)-$0.03-400%

Balance sheet

See full
Cash & equivalents$19.2M-48.8%
Total debt$514.0K-52.8%
Total equity$258.7M+212%
Total assets$274.0M+165%

Cash flow

See full
Operating cash flow-$6.0M+61.8%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$903.36M+5.0%
Enterprise value$884.71M+5.4%
P/E5.9×—
P/S5×-53.9×

Profitability

See full
Operating margin82%+44.9pp
Net margin84.2%+46.6pp

Returns & leverage

See full
Return on equity89.6%+65.3pp
Debt / equity0×0.0×
Current ratio81.4×+60.9×

Segments

By product

See full
Revenue from collaborations and licenses$632.0K-93.4%
Non-cash royalty revenue$180.0K-65.8%

By segment

See full
Reportable Segment$1.0M-90.6%

FAQ

When did Arbutus Biopharma Corporation report Q2 2026 earnings?
Arbutus Biopharma Corporation (ABUS) reported Q2 2026 earnings on August 12, 2026 before market open.
What were Arbutus Biopharma Corporation's Q2 2026 revenue and EPS?
Arbutus Biopharma Corporation reported revenue of $1.0M and eps of $-0.03 for Q2 2026.
Did Arbutus Biopharma Corporation beat estimates in Q2 2026?
Revenue beat the consensus estimate of $700.0K by $314.0K. EPS missed the consensus estimate of $-0.02 by $0.01.
How did Arbutus Biopharma Corporation's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 90.6% from $10.7M a year earlier.
Where can I find Arbutus Biopharma Corporation's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-005442) and the 10-Q periodic report (0001447028-26-000045) directly on SEC EDGAR. The filing index links above go to sec.gov.